[BIOS 332] Introduction to Information - Jason Tresser
BIOS 332: Genetics Introduction to Information September 24, 2012From:BiolaUniversityViews:5 0ratingsTime:16:47More inEducation

Go here to read the rest:
[BIOS 332] Introduction to Information - Jason Tresser - Video

Recommendation and review posted by Bethany Smith

[BIOS 332] Eukaryotic Gene Regulation - Jason Tresser
BIOS 332: Genetics Eukaryotic Gene Regulation November 28, 2012From:BiolaUniversityViews:1 0ratingsTime:47:43More inEducation

Originally posted here:
[BIOS 332] Eukaryotic Gene Regulation - Jason Tresser - Video

Recommendation and review posted by Bethany Smith

21 y/o Natural Bodybuilder - Polska Genetics: some posing attempts to metallica 1.90cm / 105kg
One my new favorit pull exercises. Please like subscribe and share this video with all your friends on Facebook, Twitter etc. For personal online coaching, go check out my homepage: http://www.polskagenetics.com Check out my Facebook Page for Updates and News as well. http://www.facebook.com http://www.facebook.com Intro by. http://www.youtube.comFrom:mousch66Views:599 48ratingsTime:03:26More inSports

More here:
21 y/o Natural Bodybuilder - Polska Genetics: some posing attempts to metallica 1.90cm / 105kg - Video

Recommendation and review posted by Bethany Smith

Washington, December 22 (ANI): In a new study, researchers have got greater insight into the safety and effectiveness of gene therapy to rebuild blood vessels in patients living with coronary artery disease.

Diagnosed with severe coronary artery disease, a group of patients too ill for or not responding to other treatment options decided to take part in a clinical trial testing angiogenic gene therapy to help rebuild their damaged blood vessels.

More than 10 years later, in a follow-up review of these patients, doctors at Baylor College of Medicine, Weill Cornell Medical College and Stony Brook University Medical Center report the outcomes are promising and open the door for larger trials to begin.

The study followed 31 Weill Cornell patients who were diagnosed with severe coronary artery disease and were given a direct injection into their heart muscle of gene therapy called adenovirus encoding angiogenic growth factor, or AdVEGF121.

Study results show the five- and 10-year survival rate of those patients were just as good and, in some cases better, than what is seen in other groups with similar heart issues treated with traditional medical therapy.

"The results of this 10-year gene therapy study are important," co-senior author Dr. Ronald G. Crystal from Weill Cornell Medical College said.

"After long-term follow-up, the patients who received angiogenic gene therapy appear to have improved outcomes. The study results give us greater insight into the safety and effectiveness of gene therapy to rebuild blood vessels in patients living with coronary artery disease," he said.

The common treatment for severe coronary artery disease is coronary artery bypass surgery, which works by redirecting blood flow around the diseased or blocked area of the heart. However, for those involved in this trial, the blood vessels that normally would be used to redirect the flow of blood were not healthy enough to do so.

In the study, patients were divided into two groups. Group A received both conventional coronary artery bypass grafting and gene therapy, while group B received only gene therapy. There was no control group.

The gene therapy helped rebuild weak and damaged blood vessels in these patients. Medical records, follow-up interviews and questionnaires were used to determine patient outcomes.

Read more here:
Gene therapy offers new ray of hope to severe coronary artery disease patients

Recommendation and review posted by Bethany Smith

Stem Cell Therapy Market in Asia Pacific to 2018 Commercialization
From:Anjali KalanViews:0 0ratingsTime:00:14More inPeople Blogs

See more here:
Stem Cell Therapy Market in Asia Pacific to 2018 Commercialization - Video

Recommendation and review posted by simmons

New Cerebral Palsy Treatment in India
She is a known case of CP with history of full term emergency caesarean section, due to fetal distress and prolong labour, she did not cry at birth and had low APGAR score. She even has history of jaundice on 3rd day of life and was given phototherapy. She was then diagnosed as Hypoxic Ischaemic Encephalopathy. Since then she has been having delayed motor milestones. Neurologically, she is hypertonic and hyperreflexic. On examination:She has poor voluntary control of bilateral lower extremities and fair voluntary control of right upper extremity, but poor voluntary control of left upper extremity; She has no speech developed. She has poor oromotor control and is on semisolid diet. Functionally, she is completely dependent for all ADL and mobility. After Stem Cell Therapy 1. Her drooling has reduced. 2. Tongue lateral movements and elevation initiated. 3. Pursing also initiated. 4. Sucking and chewing initiated. 5. Vocalizations and babbling increased. 6. Blowing initiated. 7. She can stand with minimal support, parallel bar holding from one hand, push knee splint with AFO. Earlier, she had never stood. 8. Her trunk and neck control improved. 9. Her sitting balance and posture is improved. Earlier, she could easily fall to sides with support. Now, she can maintain erect sitting for 5-10 minutes with minimal support. 10. Her left hand opening, weight bearing, grasp and overall usage increased. Now, she reaches to objects. 11. In parallel, with splint on left leg, she can do ...From:neurogenbsiViews:16 1ratingsTime:15:51More inScience Technology

Continue reading here:
New Cerebral Palsy Treatment in India - Video

Recommendation and review posted by simmons

Energy, in fact, is never lost: a fundamental law of the universe is the conservation of energy, which states that in a system isolated from all other outside factors, the total amount of energy remains the same, though transformations of energy from one form to another take place. Thermal energy is actually a form of kinetic energy generated by the movement of particles at the atomic or molecular level: the greater the movement of these particles, the greater the thermal energy. Temperature, heat, and related concepts belong to the world of physics rather than chemistry; yet it would be impossible for the chemist to work without an understanding of these properties.
When people use the word “heat” in ordinary language, what they are really referring to is “the quality of hotness”—that is, the thermal energy internal to a system. In scientific terms, however, heat is internal thermal energy that flows from one body of matter to another or, more specifically, from a system at a higher temperature to one at a lower temperature. Temperature may be defined as a measure of the average internal energy in a system. Two systems in a state of thermal equilibrium have the same temperature; on the other hand, differences in temperature determine the direction of internal energy flow between two systems where heat is being transferred.Source:
http://gundulshare.blogspot.com/2012/12/energy-heat-and-temperature.html

Recommendation and review posted by Bethany Smith

What Happened? My Afternoon Siesta
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:01:53More inNonprofits Activism

Originally posted here:
What Happened? My Afternoon Siesta - Video

Recommendation and review posted by sam

A Simple Tea-Bowl Ceremony
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:01:13More inNonprofits Activism

Continued here:
A Simple Tea-Bowl Ceremony - Video

Recommendation and review posted by sam

Warm Water Therapy: A Primary Tool For SCI and Many Other Physical Challenges
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:02:29More inNonprofits Activism

Read the rest here:
Warm Water Therapy: A Primary Tool For SCI and Many Other Physical Challenges - Video

Recommendation and review posted by sam

Horses and Equine Therapy -- Feeling Ambulation in Your Body
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:01:16More inNonprofits Activism

Continue reading here:
Horses and Equine Therapy -- Feeling Ambulation in Your Body - Video

Recommendation and review posted by sam

How I Went Far Beyond What Others Said Were Possible. A Look At Healing Modalities and Possibilities
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:11:56More inNonprofits Activism

Follow this link:
How I Went Far Beyond What Others Said Were Possible. A Look At Healing Modalities and Possibilities - Video

Recommendation and review posted by sam

Caregiving? It #39;s Complicated
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:06:14More inNonprofits Activism

See the rest here:
Caregiving? It's Complicated - Video

Recommendation and review posted by sam

Breath and Breathing: A Conscious Tool For Well-Being
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:00:39More inNonprofits Activism

See the rest here:
Breath and Breathing: A Conscious Tool For Well-Being - Video

Recommendation and review posted by sam

Attitude: A Tool for Well-Being
This is an excerpt from the film MOMENT by MOMENT, the story of a determined woman #39;s physical and psychological recovery from a severe spinal cord injury following a dramatic automobile rollover. Watch the entire film here: concentric.orgFrom:TheConcentricMediaViews:0 0ratingsTime:07:12More inNonprofits Activism

Go here to see the original:
Attitude: A Tool for Well-Being - Video

Recommendation and review posted by sam

Robot Bionic Suit Helps Paralyzed Patients Walk Again
Robot Bionic Suit Helps Paralyzed Patients Walk Again A new bionic suit is helping paralyzed patients walk again. Spinal cord injury patient Aaron Bloom has been training with the device for three months. It was first designed to help soldiers carry heavy loads, but is not helping patients balance. Bloom said, "It #39;s great to be upright and walking." The $150000 suit and its use in therapy are not covered by insurance, but rehab specialists say the device can help patients in many ways, including keeping their bones strong.From:hourlyupdatesViews:0 0ratingsTime:02:03More inScience Technology

Go here to read the rest:
Robot Bionic Suit Helps Paralyzed Patients Walk Again - Video

Recommendation and review posted by sam

Back to the Future Academic Conference: Fiorenzo Omenetto and David Kaplan
Watch Dr. David Kaplan and Fiorenzo Omenetto #39;s "The New Silk: A Thread of Discovery" as it was given at Tufts University #39;s Back to the Future event on Tuesday, November 27, 2012 at the Harmonie Club in NYC. Dr. David Kaplan, the Stern Family Professor of Engineering, is a professor and chair of the Department of Biomedical Engineering and holds faculty appointments in the Department of Chemical and Biological Engineering, Department of Chemistry, the Tufts University School of Medicine, and the Tufts University School of Dental Medicine. He has pioneered the study of silk-based biomaterials in regenerative medicine. Fiorenzo Omenetto, Ph.D., the Frank C. Doble Professor in Engineering, is a professor in the Departments of Biomedical Engineering and Physics, and leads the laboratory for Ultrafast Nonlinear Optics and Biophotonics. He has pioneered, with David Kaplan, the use of silk as a material platform for photonics, optoelectronics, and high-technology applications.From:TuftsAlumniViews:4 0ratingsTime:20:28More inEducation

Go here to read the rest:
Back to the Future Academic Conference: Fiorenzo Omenetto and David Kaplan - Video

Recommendation and review posted by sam

Myelin Repair - The People #39;s Hot Topic with Prof. Siddharthan Chandran
Siddarthan Chandran, professor, neurologist and general cricket fanatic answers your questions on Myelin Repair. Siddarthan is the director of the Anne Rowling Clinic for regenerative medicine at the University of Edinburgh - he took some time to meet with Shift.ms and talk to us about some of the work he and his collaborators are doing around myelin repair. Apologies about some of the filming - the camera was on the wrong setting!From:shiftdotmsViews:17 1ratingsTime:11:42More inNonprofits Activism

Continue reading here:
Myelin Repair - The People's Hot Topic with Prof. Siddharthan Chandran - Video

Recommendation and review posted by sam

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/gvftjr/global) has announced the addition of the "Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies (Lipofection, Calcium Phosphate, Electroporation, Nucleofection, Magnetofection, Gene Gun, Viral) Market (2012 - 2017)" report to their offering.

Transfection is an enabler technology used for many cell based research activities with applications spanning production of recombinant proteins and recombinant cell lines, gene therapy, delivery of therapeutics and also drug discovery. This research report provides a brief description on transfection technologies, its evolution, comparative analysis, market landscape analysis, competitive scenario and emerging technology and application trends. Global research and development Network, Innovation and Spin offs have been discussed. The report tracks regional adoption and development trends, providing strategic recommendation to stay active and compete in the market space. An impact analysis of major drivers and restraints influencing the growth of the market is mapped for five year period.

Key Driver:

Advances in cell research and therapeutic delivery

Cell research is a major driving factor for transfection market, as more than 60% of the users are of academic institutions and researchers. Research in gene transfer is being performed in in vivo conditions for different therapeutic applications; there is a growing demand for new transfection technologies to address unmet needs for therapeutic delivery which is driving the transfection market.

Key Restraint:

Home brew Reagents restricts sale of commercial kits

Home brew reagents are still the preferred choice of reagents for transfection by researchers all over the world. Most of the researchers prepare their own reagents from their laboratory to conduct their research. This is true for most of the reagent based transfection reactions. This allows them to reduce cost involved in purchasing commercial kits.

Key Challenge:

Original post:
Research and Markets: Global Transfection (Gene Delivery, DNA Delivery, Protein Delivery, SiRNA Delivery) Technologies ...

Recommendation and review posted by Bethany Smith

Christmas Party 2012 - Gangnam Girls
II- Genetics Christmas Party Dec. 20, 2012 ^^ Song: Remix~ By: Remix! Dancers: April, Rox, Mai.o2, Ganda (Grace xD), Alyssa Camera: Me :DFrom:Rui Musume KageneViews:0 0ratingsTime:03:53More inEntertainment

See the original post:
Christmas Party 2012 - Gangnam Girls - Video

Recommendation and review posted by Bethany Smith

Plan My Baby. Baby gender predictor, Can you really choose your baby #39;s gender? Testimonial.
yupurl.com - Plan My Baby. Baby gender predictor, Can you really choose your baby #39;s gender? Testimonial. What you hear in the short video testimonial above is true story the persons who follow the this program. The owner of "Plan My Baby" program claim the method they use is 94% accurate base on some people already follow they program. Baby gender predictor is actually a controversial topic, especially in relation to genetic therapy as well as ethics of picking the sex of your respective child. While there certainly have already been advances in the field of genetics, you can get some natural and completely ethical issues that it can be done will increase the chance of deciding on a gender on your child. While no strategy is 100% accurate, for anyone who is determined to possess a boy or perhaps a girl, usually there are some issues that can be carried out to significantly grow your chances of conceiving the gender which you decide on. Remember, it is important will be to use a healthy baby, regardless of their gender. But if you need to do would like to try to decide on the gender of one #39;s child or baby gender predictor it will be easy. Some tips about what consider know. Variations in Sperm. The sperm that carry the Y chromosome are classified as the "boy" sperms, as you move the ones that carry the X chromosome are definitely the "girl" sperms. The Y sperm are faster, smaller, more agile however tend not to last as long as the "girl" sperm. The X sperm are bigger and ...From:planmybaby80Views:0 1ratingsTime:02:50More inNews Politics

Read the original post:
Plan My Baby. Baby gender predictor, Can you really choose your baby's gender? Testimonial. - Video

Recommendation and review posted by Bethany Smith

"Bucca" German Shepherd with strong genetics for bite work! http://www.K9-1.com
We recently were giving the opportunity to use Bucca as a stud for our most recent German Shepherd litter with our very strong and stable female Nora. This is a demo of the dog #39;s BITE and not his training. All pups will be placed with either experienced working handlers or with training and handler lessons at our facility. Dog training, personal protection dog sales, and courses for the dog training student available at our facility. Contact us at http://www.k9-1.comFrom:k91dogtrainingViews:103 4ratingsTime:02:00More inPets Animals

Originally posted here:
"Bucca" German Shepherd with strong genetics for bite work! http://www.K9-1.com - Video

Recommendation and review posted by Bethany Smith

Genetics in Edinburgh: the early days
A journey through the birth of genetics at Edinburgh, via our Towards Dolly projectFrom:euarchivesViews:0 0ratingsTime:02:31More inNews Politics

See more here:
Genetics in Edinburgh: the early days - Video

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Dec 20, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) today announced financial results for the third quarter of 2012, ended September 30, 2012.

"During the third quarter of 2012, we successfully completed our initial public offering of 800,000 shares at $5.00 per share, the midpoint of our price range. The proceeds from the IPO will enable us to accelerate the national roll-out of our first FDA-cleared and marketed product, the ForeCYTE Breast Health Test for breast cancer risk assessment," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO. "Our IPO was the only biotech IPO priced in the month of November and was priced in the immediate aftermath of Hurricane Sandy. I believe this is a testament to the strength of our business model and the significant revenue and earnings potential of Atossa Genetics over the next several years as we pursue the further commercialization of the ForeCYTE and ArgusCYTE tests with the 5,000-strong launch team through our marketing partner, Diagnostics Testing Group, LLC, the commercialization of two new tests in 2013, and the advancement of our intraductal therapeutics program to safely and effectively treat pre-cancerous breast lesions."

Third Quarter 2012 Results

Total revenues for the third quarter of 2012 were $105,576, comprising $104,011 in diagnostic testing services and $1,565 in product sales, versus no revenues for the third quarter of 2011. The ForeCYTE and ArgusCYTE tests were launched through a field experience trial beginning in December 2011 and are expected to be rolled out nationally starting in early 2013.

Gross margin for the third quarter was 86 percent on gross profit of $90,499.

Operating expenses are comprised of selling, general and administrative (SG&A) expenses and research and development. For the third quarter of 2012, total operating expenses were $1.23 million versus $1.27 million for the third quarter of 2011.

Net loss for the third quarter ended September 30, 2012, was $1.14 million, or ($0.10) per share, versus a net loss of $1.27 million, or ($0.11) per share, for the year-ago quarter.

As of September 30, 2012, the Company had cash and cash equivalents of $418,570 versus $1.91 million at the end of December 2011. The company completed its IPO in November 2012, raising $4.0 million in gross proceeds prior to expenses and net proceeds of approximately $3.5 million.

Corporate Highlights

About Atossa Genetics, Inc.

Read the original here:
Atossa Genetics Announces Third Quarter 2012 Financial Results

Recommendation and review posted by Bethany Smith

SEATTLE, WA--(Marketwire - Dec 21, 2012) - Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, announced today that Christopher S. Destro has joined the Company as Vice President of Sales and Marketing, reporting to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President. Mr. Destro, an industry veteran with over 16 years of successful sales and client management expertise within the clinical sector of diagnostic biotechnology, will be responsible for product marketing, distribution and sales.

"The Company is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time," said Dr. Quay. "As we accelerate the national roll-out of our ForeCYTE and ArgusCYTEBreast Health Tests in early 2013, Chris' extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives."

"Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company's products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women's lives," commented Mr. Destro. "Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa's growth as we expand the commercialization of our innovative products and services in the U.S."

Mr. Destro continued, "One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever."

From 2007 to 2011, Mr. Destro, (42), served in increasingly responsible positions including Vice President of Sales, North America, for three divisions of Magellan Biosciences, where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex and a lead care platform for Point of Care testing. In July 2011, Magellan was acquired by Thermo Fisher Scientific, where Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets.Prior to joining Magellan, Mr. Destro served as Americas Sales Director for International Bioproducts from 2000 to 2007, where he managed sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.

On December 20, 2012, and as an inducement to cause Mr. Destro to join the Company, he was awarded an option to purchase a total of 200,000 shares of common stock of the Company, par value $0.001 per share, outside the Company's 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date and vests over a four-year period from his commencement of service. This stock option was granted as an inducement material to Mr. Destro's entering into employment with the Company and is being reported in accordance with NASDAQ Listing Rule 5635(c)(4).

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

For more information about this press release, please click the following link: http://client.irwebkit.com/AtossaGenetics/media to view a video interview with Dr. Quay discussing Atossa Genetics and Christopher Destro's role with the Company. You may also sign up to receive automatic email News Alert updates.

Visit link:
Christopher S. Destro Joins Atossa Genetics as Vice President of Sales and Marketing

Recommendation and review posted by Bethany Smith